Ceftazidime/avibactam (Zavicefta®)

Assessment Status Rapid Review complete
Drug Ceftazidime/avibactam
Brand Zavicefta®
Indication For the treatment of CIAI, cUTI, HAP (including VAP) and gram negative infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
Assessment Process
Rapid review commissioned 17/05/2017
Rapid review completed 13/06/2017
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended at the Submitted Price

The HSE has approved reimbursement following confidential price negotiations November 2017.